Menu

Diagnostic Tests and Clinical Procedures

Since quality of the diagnostic process largely determines quality of care, overcoming deficiencies in standards, methodology, and funding deserves high priority. This category summarises objectives of diagnostic testing and research, methodological challenges, and options for design of studies.

Percutaneous Thrombectomy an Option in Some Cases of Pulmonary Embolism

Combined clot fragmentation and thrombus aspiration appears to be beneficial in certain patients with massive angiographic pulmonary embolism (PE), according to Mexican researchers.

Read more: Percutaneous Thrombectomy an Option in Some Cases of Pulmonary Embolism

CK19 MRNA Expression Identifies Lymph Node Metastases Intraoperatively

Measurement of CK19 mRNA expression intraoperatively can be used as a rapid diagnostic method to detect lymph node metastases in women with breast cancer, according to a report in the June 1st issue of the International Journal of Cancer.

Read more: CK19 MRNA Expression Identifies Lymph Node Metastases Intraoperatively

Quest Diagnostics and Google Empower Patients and Physicians to Share Diagnostic Test Results Online

MADISON, N.J., May 19 /PRNewswire-FirstCall/ -- Patients and physicians have a new way to share diagnostic laboratory data online, thanks to Quest Diagnostics and Google Health, a product launched today by Google. More than 100,000 physicians in the U.S. who use Quest Diagnostics' family of Care360(TM) connectivity products will be able to securely provide diagnostic data with a brief explanation of test results to a patient's Google Health Account, where a patient can maintain medical records and personal health information online. The new product is expected to empower patients and physicians to collaborate more closely in making more well-informed health care decisions based on diagnostic information. Quest Diagnostics Incorporated (NYSE: DGX) is the nation's leading provider of diagnostic testing, information and services, serving half of all physicians and hospitals in the U.S. and analyzing test results for more than 500,000 patients every day. Quest Diagnostics is the only diagnostic testing company collaborating with Google to launch Google Health.

Read more: Quest Diagnostics and Google Empower Patients and Physicians to Share Diagnostic Test Results Online

Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening

Enterix Inc., a wholly-owned subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced the availability of the InSure(R) Quik F I T(TM) fecal immunochemical test, a point-of-care version of the company's lab-based InSure(R) FIT(TM) test, that provides physicians with the sensitivity and specificity of the laboratory-based InSure FIT test.

Read more: Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening

Quest Diagnostics Announces Annual Shareholder's Meeting Webcast

Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, will conduct its annual meeting of shareholders on Friday, May 16th at 10:30 am ET.

Read more: Quest Diagnostics Announces Annual Shareholder's Meeting Webcast

Quest Diagnostics Is Named 'Best Employer For Healthy Lifestyles'

Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced today that the National Business Group on Health (NBGH), an association of more than 300 large U.S. employers, has presented its 2008 Best Employers for Healthy Lifestyles Gold Award to the company for its HealthyQuest employee wellness program. In its second consecutive year as Gold Award recipient, Quest Diagnostics is one of only seven companies to have received the NBGH Healthy Lifestyles awards in the four years the awards have been given. The company was honored with the Silver Award in 2006 and 2005.

Read more: Quest Diagnostics Is Named 'Best Employer For Healthy Lifestyles'

Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008

Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the first quarter ended March 31, 2008, income from continuing operations was $141 million, or $0.72 per diluted share, compared to $108 million, or $0.55 per diluted share, in the first quarter of 2007. Included in the results for the first quarter of 2007 were special charges of $0.04 per diluted share principally associated with workforce reductions.

Read more: Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008

Everything You Need to Know About Hair Testing For Drugs of Abuse

DESCRIPTION
An educational and interactive look at the often-misunderstood world of hair testing for drugs of abuse in the workplace. The discussion will include the benefits of hair testing, how to perform the collection, the science behind the test, current regulations and a comparison of hair testing against urine and oral fluid screening. Bring along your questions, as a part of the hour will be dedicated to getting you the answers you need.

Read more: Everything You Need to Know About Hair Testing For Drugs of Abuse

Amount: 

Color I Color II Color III

Log In or Register